Survival according to tertiles of copeptin.

<p>Survival according to tertiles of copeptin in the total cohort (A), in medical patients (B) and in patients that were admitted due to cardiac surgery or heart valve intervention (C);</p

Clinical and demographic baseline characteristics of the study population.

<p>Clinical and demographic baseline characteristics of the study population.</p

Copeptin serum levels and 30 day survival.

<p>Serum levels of copeptin in 30-day survivors and non-survivors in the total cohort (A), in medical patients (B) and in patients that were admitted because of cardiac surgery or heart valve intervention (C); outliers not shown; * p<0.05; ¶ p<0.005</p

Multiple Cox regression model for prediction major adverse cardiac events (MACE: the composite of acute coronary syndrome, stent thrombosis and cardiac death).

<p>HTPR: high on treatment platelet reactivity.</p

Adapted path model including the DACC score as an independent variable predicting high on treatment platelet reactivity (HTPR); Age and HTPR as independent predictors of major adverse cardiac events (MACE: the composite of acute coronary syndrome, stent thrombosis and cardiac death).

<p>Paths from independent to dependent variables represent standardized estimates. *p<0.05; ACS: acute coronary syndrome; CYP: cytochrome P450.</p

Patient demographics.

<p>Data are reported as Mean ± standard deviation (SD), n (number of patients) or percentages; CAD: coronary artery disease; PCI: percutaneous coronary intervention; NSTE-ACS: non ST- elevation acute coronary syndrome, STEMI: ST- elevation myocardial infarction. ABCB1: gene encoding transmembrane transporter P-glycoprotein; PON1: paroxonase 1.</p

Univariate logistic regression for prediction of high on treatment platelet reactivity (HTPR).

<p>ACS: acute coronary syndrome; BMI: body mass index; GFR: glomerular filtration rate; CAD: coronary artery disease; CYP: cytochrome P450; ABCB1: gene encoding transmembrane transporter P-glycoprotein; PON1: paroxonase 1.</p

Incidence of increased % of patients with high on treatment platelet reactivity (HTPR) according to cumulative number of score variables.

<p>ACS: acute coronary syndrome; DM: diabetes mellitus; CYP: cytochrome P450.</p

Survival analysis according to the high on treatment platelet reactivity (HTPR) and age.

<p>MACE: major adverse cardiac events: the composite of acute coronary syndrome, stent thrombosis and cardiac death; PCI: percutaneous coronary intervention.</p

Path modelling results.

<p>ACS: acute coronary syndrome; BMI: body mass index; GFR: glomerular filtration rate; CYP: cytochrome P450; ABCB1: gene encoding transmembrane transporter P-glycoprotein; PON1: paroxonase 1; HTPR: high on treatment platelet reactivity; MACE: major adverse cardiac events (MACE: the composite of acute coronary syndrome, stent thrombosis and cardiac death).</p